Cantabria experimentará la mayor renovación tecnológica de su sistema sanitario
El Diario Montañés
Sanidad manejará un presupuesto de 8249 millones en 2017 un 238 más
El Diario Montañés El Diario.es El Médico Interactivo
l Patronato del IDIVAL aprueba el presupuesto y los planes de investigación y actuación para 2017
El Diario.es ABC
Identifican varios genes implicados en los linfomas de células T periféricos
La Vanguardia El Diario Montañés El Norte de Castilla El Digital de Asturias Salamanca 24 Horas
T lymphocytes are blood cells whose mission is to destroy the malignant cells that affect our organism. They fight against diseased cells that sometimes originate in organs or those that have been infected by viruses. However, when they undergo certain genetic alterations they can cause tumors such as peripheral T-cell lymphomas, which have a very high mortality rate.
In addition to their aggressiveness, another reason that hinders their treatment is that they are not easy to identify. Usually 30% are diagnosed as T-lymphomas of unclear origin.
This week, an international group of scientists, in which IDIVAL participates, has published in the prestigious journal PNAS the results of a study that identifies several of these altered genes in T-cell lymphomas of unclear origin.
One of them is the proto-oncogene VAV1, which is usually found with genetic alterations in 12% of the patients analyzed. The same gene appears at lower frequencies (between 3% and 7% of cases) in another tumor with similar malignant properties, angioinmunoblastic T-cell lymphoma.
“The interesting thing is not only the fact that we have found mutations with high frequency in the VAV1 gene in these tumors, but also that many of these originate hyperactive molecules that probably contribute to the development of this type of tumor”, explains Xosé R. Bustelo, a scientist of the CIC and one of the authors of the work.
In addition, advancement may aid in the treatment of this lymphoma with drugs: “Since the VAV1 oncoprotein has a biological activity that is potentially feasible to be inhibited by drugs, these findings also establish a potential target for the development of more effective pharmacological treatments,” Says Javier Robles, researcher of the Bustelo team.Numerous genetic alterations
In any case, one of the difficulties to be faced is that these tumors are very heterogeneous and have numerous genetic alterations. “Depending on the type of mutations they host, there will be patients who will exhibit different clinical behaviors in both their clinical course and response to treatments,” the authors write.
The complexity they describe implies that they should still continue research to extend the study to a large number of patients, so that they can assign to each molecular signature a specific clinical behavior.
The work is coordinated by Spanish researchers Teresa Palomero and Adolfo Ferrando, whose research groups are at the Institute for Cancer Genetics at Columbia University in New York. Also participating are centers such as the Institute of Biomedical Research Pi i Sunyer of Barcelona and IDIVAL the Institute of Sanitary Research of Valdecilla of Santander, among others.
An international group of scientists in which it participates in idival has achieved to identify various genes altered in peripheral T-lymphomas
T lymphocytes are blood cells whose mission is to destroy the malignant cells that affect our organism. They fight against diseased cells that sometimes originate in organs or those that have been infected by viruses. However, when they undergo certain genetic alterations they can cause tumors such as peripheral T-cell lymphomas, which have a very […]
The Board of IDIVAL at its meeting on December 16th approved the update of its composition with the incorporation of the following researchers:
– Marcos López Hoyos. Coordinator of the Transplant Area of Organs and Tissues and New Therapies. Head of Immunology Service. University Hospital Marqués de Valdecilla. It replaces Dr. Manuel Arias, recently retired.
– Fernando Rivera Herrero. Coordinator of the Cancer Area. Head of the Oncology Service. University Hospital Marqués de Valdecilla. Replaces Dr. Jose Luis Fernandez Luna.
– María Carmen Fariñas Alvarez. Coordinator of the Area of Infectious Diseases and Immune System. Head of the Infectious Service. University Hospital Marqués de Valdecilla. Professor of the Department of Medicine and Psychiatry. University of Cantabria. Replaces Dr. Luis Martinez, who has moved to another center.
– Javier Crespo García. Head of the Digestive Service. University Hospital Marqués de Valdecilla. Professor of the Department of Medicine and Psychiatry. University of Cantabria.
The Internal Scientific Council of IDIVAL is made up of IDIVAL researchers, including representatives of the Institute's research areas. Advises and supports the IDIVAL Directorate in its tasks and specifically in the elaboration of the Strategic Plan, the annual operational programs and in the annual reports of activities of the Institute and is a bidirectional channel of communication, exercising the transmission of the needs raised by the heads of the Research Groups to the Management.
The current composition of the Internal Council can be consulted at the following link
IDIVAL renews its internal scientific council with the incorporation of four new members
The Board of IDIVAL at its meeting on December 16th approved the update of its composition with the incorporation of the following researchers: – Marcos López Hoyos. Coordinator of the Transplant Area of Organs and Tissues and New Therapies. Head of Immunology Service. University Hospital Marqués de Valdecilla. It replaces Dr. Manuel Arias, recently retired. […]
El Hospital Universitario Marqués de Valdecilla repite como el mejor hospital cántabro
La Vanguardia
El Hospital Virtual nuevo canal de formación para el cuidado del paciente crónico
El Diario Montañés
La ITV del cuerpo humano
El Diario Montañés
Interreg Sudoe Program´s Monitoring Committee has approved the basis for the second call for projects.
Beneficiaries have two months to prepare their proposal that will have to send from 13 to 31 March (both included).
With a budget of EUR 25 million from the European Regional Development Fund (ERDF), this new call for projects opens up to two axes:
Axis 1 – Promoting innovation capacities for smart and sustainable growth (€ 16 million).
Axis 5 – Protecting the environment and promoting resource efficiency (€ 9 million).
Any doubt or consult about the current SUDOE Programme you can contact European Projects team of IDIVAL: Lorena Agüero Cobo (projects1@idival.org) and Paloma Gonzalez Alvarez (innovacion4@idival.org).
Second call for projects Interreg Sudoe Program
Interreg Sudoe Program´s Monitoring Committee has approved the basis for the second call for projects. Beneficiaries have two months to prepare their proposal that will have to send from 13 to 31 March (both included). With a budget of EUR 25 million from the European Regional Development Fund (ERDF), this new call for projects […]
